5/15/2023 7:45:57 AM
Minerva Neurosciences Q1 Net Loss $7.0 Mln Or $1.31/Shr Vs Loss Of $9.8 Mln Or $1.83/Shr Last Year
3/8/2023 7:43:59 AM
Minerva Neurosciences Q4 Net Loss $6.7 Mln Or $1.26/Shr Vs Loss Of $21.3 Mln Or $3.99/Shr Last Year
11/9/2022 8:09:23 AM
Minerva Neurosciences Q3 Net Loss $6.9 Mln Or $1.29/Shr Vs Loss Of $9.2 Mln Or $1.72/Shr Last Year
10/17/2022 8:42:26 AM
Minerva Gets Refusal To File Letter From FDA For Roluperidone NDA For Negative Symptoms In Schizophrenia
9/30/2021 8:38:22 AM
Minerva Neurosciences Announces Results From Pivotal Bioequivalence Study For Negative Symptoms Of Schizophrenia
5/12/2021 7:38:11 AM
Minerva Neurosciences Q1 Net Loss $8.8 Mln Or $0.21/Shr Vs Loss $12.2 Mln Or $0.31/Shr Last Year